Kornimate/medical-research-clean huggingface dataset:
relationship between gastroesophageal reflux disease and dental erosion

Conditions: Gastroesophageal Reflux Disease; Tooth Wear

Summary: this study aimed to investigate the relationship between gastroesophageal reflux disease (gerd) and dental erosion and the alterations in oral tissues. this was a case-control study. the gerd group consisted of 50 individuals with endoscopic esophagitis who had gastroesophageal reflux symptoms, and the control group consisted of 50 healthy individuals. the prevalence of teeth wear and caries was evaluated using the smith and knight tooth wear index (twi) and the decayed, missing, and filled teeth index (dmft), respectively. inflammatory mouth sensitivity, tongue sensitivity, nonspecific itching and burning, halitosis, dry mouth, teeth sensitivity, and the erythema of the soft and hard palatal mucosa and uvula were also evaluated. stimulated saliva samples were collected, and the salivary flow rate, ph, and buffering capacity values were measured.


Eligibility criteria:
inclusion criteria: * the patient group included with at least one year of reflux symptoms, endoscopic esophagitis, no systemic disease other than reflux, no medication use except anti-reflux drugs, no habit of ruminating and vomiting, and no habit of bruxism. * the control group included without any systemic disorder, no habit of ruminant and vomiting, no habit of bruxism, and no drug use. exclusion criteria: * the volunteers who were vegetarian, consumed citrus and vinegar frequently, and consumed more than ½ liter of acidic beverages per day were not included in the study. those who never brush their teeth and were using battery/rechargeable and scrub brush and abrasive toothpaste were not included in the study, either.

Keywords: dental erosion dmft gastroesophageal reflux disease saliva
euphrasia eye drops in preterm infants with first signs of congestion of nasolacrimal duct

Conditions: Congenita Nasolacrimal Duct Obstruction; Preterm Neonates; Ocular Discharge

Summary: congenital nasolacrimal duct obstruction (cnldo) occurs in approximately 10 to 20% of all term newborns, and is the most common cause of persistent tearing and ocular discharge in children. cnldo causes symptoms in up to 6% of children during the first year of life. the first clinical signs appear during the first month of life in 95% of cases and usually consist of tearing and debris on the eyelashes ("mattering"). mucopurulent eye discharge occurs commonly in infants with cnldo and, in the absence of other signs of infection, suggests bacterial overgrowth in the stagnant tear pool of the lacrimal sac. this study investigates whether early administration of euphrasia eye drops (weleda ag, arlesheim) in preterm neonates presenting with first ocular discharge with or without tearing and reddened eye fosters the resolution of the ocular discharge and reduces the need for topical antibiotic therapy.


Eligibility criteria:
inclusion criteria: * preterm neonates (with a gestational age of 24 to 37 weeks) * presenting with first signs of a congestion of the nasolacrimal duct, i.e. white, yellow, or green ocular discharge with or without tearing and reddened eye. * written informed consent by the parents or legal guardians exclusion criteria: * congenital abnormalities of the eye * ophtalmia neonatorum * severe asphyxia * sepsis * intracranial bleeding (intraventricular hemorrhage ≥ grade iii)
efficacy of modified ketogenic diet (atkins) in management of epilepsy

Conditions: Epilepsy

Summary: the purpose of this study is to determine whether patients with uncontrolled epilepsy can follow a low carbohydrate diet long-term and if so, how will that diet affect their seizures

in the management of drug-resistant epilepsy, many strategies have been examined. the ketogenic diet, high in fats and low in all other nutrients was observed to be of benefit. however, due to its complexedness and unpalatability, this diet is rarely used in the adult population. a recent small study showed seizure reduction with the atkins diet. in this study, patients will be randomized into one of 2 groups- group 1 receiving limited dietary instruction for the atkins diet and group 2- receiving detailed dietary instruction. a seizure severity-matched control group will also take part. we will follow these patients over a period of 2 years looking at seizure frequency, weight, sustainability of the diet, effect on anti-epilepsy medication dosage, effect in cognition, quality of life and financial impact of the diet. patients will come to clinic to see the dietitian at specific intervals. cognitive testing will also be done at the beginning of the study and every 6 months thereafter. patients will keep food charts, ketosis charts and seizure diaries.

Eligibility criteria:
inclusion criteria:medically refractory partial epilepsy financial ability to pay for higher priced food - exclusion criteria: * low bmi

Keywords: epilepsy atkins diet
alberta collaborative qi strategies to improve outcomes of moderate and late preterm infants (abc-qi trial)

Conditions: Length of Stay

Summary: the abc-qi trial aims to implement collaborative quality improvement (qi) strategies to standardize care for 32-36 week infants in level 2 and 3 neonatal intensive care units (nicus) across the province of alberta. the investigators want to know if using validated quality improvement methods and evidence-based care bundles will decrease the duration of hospital stay and get babies home as quickly as possible.

a stepped-wedge cluster randomized trial will be conducted in 12 nicus across alberta (10 level ii and 2 level iii). each nicu is considered a cluster and will be randomized to transition to the intervention arm at one of three time points. the planned trial interventions include: intervention arm (collaborative qi strategies): the study intervention is a constellation of collaborative qi strategies: 1) qi team building; 2) qi education; 3) implementation of 2 standardized practice care bundles (respiratory care, and nutritional care); 4) qi mentoring; and 5) collaborative networking. based on the randomization, 4 nicus will transition to the intervention arm at the end of each year. control arm (current management): all participating nicus will be in the control arm during the first year prior to randomization to create a baseline of the current practices and between-units variation. nicus in the control arm can continue conducting qi activities relevant to current practice, but without receiving the interventions outlined above.

Eligibility criteria:
inclusion criteria: preterm infants: infants born at 32 to 36 weeks' gestation and admitted to the participating nicus or postpartum units. quality improvement implementation survey version 2 (qiis-ii) and semi-structured interview participants: management staff, nurses, nurse practitioners, physicians, and allied health staff employed in participating nicus. exclusion criteria: * preterm infants: * major congenital anomalies or chromosomal abnormalities. * primary admission to a surgical nicu: alberta children's hospital or stollery children's hospital. * infants born in or transferred to a nicu outside alberta. * patients who have imposed confidentiality restrictions on accessing their health records.

Keywords: preterm infants evidence-based practice for improving quality neonatal intensive care units
pain and quality of life after inguinal hernia repair

Conditions: Inguinal Hernia

Summary: this study aims to explore the difference in outcomes relating to pain and quality of life after open, laparoscopic, and robotic-assisted inguinal hernia repair.

this is a prospective, multi-center, observational pilot study comparing outcomes of pain and quality of life after inguinal hernia repair between open, laparoscopic, and robotic-assisted surgical approaches. the study will focus on short-term outcomes through 3 months post-operation. during the post-operative period through 3 months, pain medication intake, pill count, subject-reported pain (on post-operative days 1-3 and 14 days post-surgery), and quality of life (at 14 days, 30 days, and 3 months post-surgery), incidence of intra- and post-operative complications, and time to return to normal activity will be collected.

Eligibility criteria:
inclusion criteria: * subject is between 18 and 80 years of age. * subject is a candidate for an elective primary inguinal hernia repair. exclusion criteria: * subject receiving a bilateral open repair. * subject who will have an emergent hernia repair. * subject with a history of chronic pain and/or taking daily pain medications for \>6 weeks. * subject with a history of substance abuse and/or current (within 30 days) narcotic use. * subject with a history of methicillin-resistant staphylococcus aureus (mrsa) infection. * diabetic subjects requiring insulin. * subject with recurrent hernias. * subject who will require the use of exparel during the surgical procedure. * subject who will undergo a concomitant hernia repair or any other concomitant procedure. * current marijuana use that the subject is unwilling to discontinue within the 14 days prior to surgery. * subject is contraindicated for surgery. * subject has a known bleeding or clotting disorder. * pregnant or suspect pregnancy. * subject is mentally handicapped or has a psychological disorder or severe systemic illness that would preclude compliance with study requirements or ability to provide informed consent. * subject belonging to other vulnerable population, e.g, prisoner or ward of the state. * subject unable to comply with the follow-up visit schedule. * subject is currently participating in another research study.
expanded access program for pirtobrutinib for participants with b-cell cancer

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Lymphocytic, Small; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Ritcher's Transformation, Syndrome

Summary: this is an expanded access program for eligible participants with a previously treated b-cell cancer who are ineligible for an ongoing pirtobrutinib clinical trial. the treating physician/investigator contacts lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.


Eligibility criteria:
inclusion criteria: * have been diagnosed with: * cll or sll and have received treatment with the following five classes of therapy: chemotherapy, anti-cluster of differentiation (anti-cd) 20 antibody, covalent bruton's tyrosine kinase (btk) inhibitor, b-cell lymphoma-2 (bcl-2) inhibitor, and phosphatidylinositol 3-kinase (pi3k) inhibitor * mcl that has been previously treated with a covalent btk inhibitor * richter's transformation (rt) with previous richter's directed-therapy * waldenstrom macroglobulinemia (wm), previously treated with chemotherapy, anti-cd20 antibody and a covalent btk inhibitor * are not eligible for an ongoing pirtobrutinib clinical trial exclusion criteria: * inadequate organ function * significant cardiovascular disease * history of allogenic or autologous stem cell transplant (sct) or chimeric antigen receptor modified tcell (car-t) therapy within 60 days * tested positive for human immunodeficiency syndrome (hiv) or known active hepatitis b or c virus or cytomegalovirus (cmv) infection * active, uncontrolled autoimmune cytopenia * clinically significant active malabsorption syndrome * participants requiring therapeutic anticoagulation with warfarin or another vitamin k antagonist

Keywords: btki btk inhibitor bruton's tyrosine kinase inhibitor hematologic disease b-cell receptor
the effect of patient cost-sharing on antidepressant and adjunctive therapy use

Conditions: Depressive Disorder, Major

Summary: the primary objective of this study is to measure the effects of patient cost-sharing on the initiation of adjunctive treatment and subsequent healthcare utilization and expenditures among a population of commercially insured adults on antidepressant therapy.


Eligibility criteria:
inclusion criteria: * adult patients (aged 18-64) will be selected from the marketscan commercial database between january 1, 2004, and september 30, 2008, if they have at least two medical claims with a diagnosis of depression and at least one prescription fill for an antidepressant medication. exclusion criteria: * patients who have any claim with a diagnosis of dementia, schizophrenia, delusional disorder, psychoses, pervasive development disorder, mental retardation, cerebral degenerations, parkinson's disease, senility, manic depression, bipolar disorder, or major depressive disorder with psychotic symptoms.
the california wisewoman project:cardiovascular(cvd) health for hispanic women

Conditions: Cardiovascular Diseases; Chronic Diseases

Summary: the purpose of this trial is to provide low-income, under- or un-insured 40- to 64-year-old women with the knowledge, skills, and opportunities to improve diet, physical activity, and other lifestyle behaviors to prevent, delay and control cardiovascular and other chronic diseases.

this study is based on a single group. evaluated how effectively culturally appropriate lifestyle intervention was in improving, over a relatively short-term period (\~12 months) on health behaviors and the cvd risk profile.

Eligibility criteria:
inclusion criteria: * national breast and cervical cancer early detection program (nbccedp)participants without cancer * income \< 200 percent of federal poverty level * under or uninsured for the health care coverage * blood pressure \>= 120 mm hg systolic or \>=80 mm hg diastolic or currently taking medication to lower cholesterol exclusion criteria: * \>180 mm hg systolic or \>110 mm hg diastolic * \> 400 cholesterol * pregnant women * had past or current cvd events

Keywords: cvd risk
treximet ™ pharmacy budget impact model database validation study

Conditions: Migraine Disorders

Summary: the purpose of this retrospective claims database study was to compare the change in migraine-related prescription (i.e. nsaids, opioids, ergots) utilization among migraine suffers following initiation of treximet ™ (sumatriptan/naproxen) compared with subjects initiating treatment with other orally available triptans. the study was used to validate the migraine-related prescription utilization patterns predicted by the treximet ™ budget impact model. the sourcelx dataset from the family of wolters kluwer databases was used for this analysis. the database contains 30% of prescription claims filled in the united states (us), approximately 160 million patient lives. the data has broad representative coverage at both the geographic and payment levels.


Eligibility criteria:
inclusion criteria: * at least one prescription claim for either treximet ™ or orally administered triptan * at least 18 years of age at index rx date * at least one prescription claim for any medication in the pre- and post-index period (proxy for continuous enrollment) exclusion criteria: * subjects receiving nasal sumatriptan at any time * subjects over 65 years of age

Keywords: triptans migraine
confident: supporting long-term care workers during covid-19

Conditions: COVID-19

Summary: the confident study is an online three-arm randomized trial that aims to help long-term care workers in the united states feel more confident about the coronavirus disease 2019 (covid-19) vaccines. the study will compare two different interventions to usual online information (website of the centers for disease control and prevention). the first intervention is a dialogue-based webinar where people can interact and ask questions about the vaccines. the second intervention is a social media website that will feature curated content about the vaccines from popular social media platforms. participants will be asked to completed four online surveys. the first survey will be completed pre-intervention and immediately upon study enrollment (time 0). participants will be randomized to a trial arm at the end of the time 0 survey. intervention follow-up surveys will be completed 3 weeks post-randomization (time 1), three months post-randomization (time 2), and 6 months post-randomization (time 3).


Eligibility criteria:
inclusion criteria: * at least 18 years of age * can read, write, and understand english * lives in the united states * has worked in a long-term care setting in the past two years * can provide information to confirm they have worked in a long-term care setting * is not pregnant or breastfeeding * at least somewhat worried about the covid-19 vaccines and/or has not received a covid-19 vaccine booster shot exclusion criteria: * under 18 years of age * cannot read, write, and understand english * does not live in the united states * has not worked in a long-term care setting in the past two years * cannot provide information to confirm they have worked in a long-term care setting * is pregnant or breastfeeding * less than somewhat worried about the covid-19 vaccines and has received at least one covid-19 vaccine booster shot
plasma modifications associated with rivaroxaban® treatment for stroke prevention

Conditions: Atrial Fibrillation

Summary: the main objective of this pilot study is to investigate the protein / peptide plasma profiles before and after treatment with a direct anti-xa (activated factor 10) in patients with non-valvular atrial fibrillation to better understand the mechanisms of action of these molecules and perform exploratory analyses concerning proteins whose concentrations change after starting treatment.


Eligibility criteria:
inclusion criteria: * the patient was correctly informed about the study, its implementation, objectives, associated restrictions and patient rights * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * the patient is available for 1 month of follow-up * the patient has non-valvular atrial fibrillation that was diagnosed within the last 3 months. documentation of atrial fibrillation by a 12-lead ecg, an ecg rhythm strip, atrial fibrillation episode lasting at least 30 seconds. * the patient has a cha2-ds2-vasc score = 1, that is to say the presence of at least one of the following risk factors: (1) congestive heart failure or moderate to severe systolic dysfunction of the left ventricle; (2) history of systolic blood pressure\> 160 mmhg; (3) diabetes; (4) history of ischemic stroke or systemic embolism; (5) vascular disease (myocardial infarction, arterial disease); (6) age \> 65 years; (7) female. * the patient will start rivaroxaban (xarelto®) at the nîmes university hospital exclusion criteria: * the patient is participating in another interventional study * the patient has participated in another interventional study within the past three months * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * the patient is pregnant, parturient, or breastfeeding * presence of a mechanical heart valve or valve disease * patient who recieved another new direct oral anticoagulant other than xarelto® in the previous three months

Keywords: xarelto® protein/peptide profiles
initial specialist telephone consultation with new patients in secondary care

Conditions: Respiratory Diseases

Summary: consultations with patients by hospital consultants are organised today in a manner which is barely dissimilar from that offered 30 or 40 years ago. whilst some attempts to improve this process, such as choose and book, shorter waiting times and patients' receiving a copy of the correspondence sent to their general practitioner (gp) have improved the situation, there has been little radical change and little thought given to the patient experience. the investigators wish to investigate whether patients' experience of attending respiratory outpatient clinics can be improved by a pre-clinic telephone call with a specialist thereby reducing the number of attendances at the hospital for appointments and investigations and improving overall patient satisfaction.

this study will investigate whether taking a new patient's history over the telephone permits better selection and arrangement of investigations prior to or synchronous with the first face to face consultation, with the potential to reduce the number of visits the patient has to make to the hospital. patients will be offered an initial telephone consultation by post and may opt-in or out of the study. those having a telephone consultation would have this booked for a specific time and date and the patient would be sent an appropriate information leaflet regarding this. after the telephone consultation patients receive a summary of the consultation and details of any investigations and appointments booked by the research nurse. patients who did not respond to the initial invitation letter within seven days or who declined to participate would be sent a routine appointment. all patients would asked to complete the miss-21 questionnaire.

Eligibility criteria:
inclusion criteria: * all new adult general respiratory referrals from primary care exclusion criteria: * follow-up patients

Keywords: outpatients
the safer at school early alert hub

Conditions: COVID-19

Summary: schools serve important community roles beyond academic education. in historically marginalized communities they are trusted providers for a range of support services for families in need. the tradeoff between these crucial benefits of in-person learning against the risk of sars-cov-2 transmission in school settings has been hotly debated throughout much of 2020 and 2021. the stakes are particularly high in historically marginalized communities which rely most heavily on school services, but have also been hit the hardest by covid-19 primarily due to structural issues. the safer at school early alert (sasea) program was co-developed by the university of california, san diego, the county of san diego, and 15 partner schools serving socially vulnerable students in 5 school districts across san diego county. sasea utilizes daily wastewater and surface (floor) environmental monitoring to detect asymptomatic sars-cov-2 infections among students and staff on campus. positive environmental signals are immediately followed by targeted responsive testing for a whole school (in the case of wastewater) or classroom (for a positive surface sample). in this project, we will develop the safer at school early alert hub (sasea hub), an online school environmental monitoring report dashboard with resources to address structural barriers to covid-19 diagnostic testing in historically marginalized communities (aim 1). we will also create a toolkit to allow any school to rapidly adapt the template to their specific setting. in aims 2 and 3, we will use a randomized stepped wedge trial to compare sasea (control) vs sasea hub (intervention) in 26 schools across 3 diverse school clusters in san diego county. our primary outcome (aim 2) is higher rates of diagnostic testing in intervention schools. our secondary outcome (aim 3) is increased risk mitigation behaviors in school community members when environmental surveillance data suggests a potential case on campus. in aim 4, we will use parent-child narrative interviews with 40 parent-student pairs to understand how children perceive covid-19 risk at school, assess differences in perceptions of testing barriers between intervention and control sites, and better understand how children understand the process of environmental surveillance and responsive testing.


Eligibility criteria:
inclusion criteria: * individuals ages 18 and above affiliated with students attending the 3 school districts participating in the sasea study exclusion criteria: * children under the age of 18